The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development

Westphalen et al. (Sun,) studied this question.

www.synapsesocial.com/papers/68e5b019b6db64358754943c — DOI: https://doi.org/10.1016/j.annonc.2024.07.730

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Navigating Change in Tumor Naming: Exploring the Complexities and Considerations of Shifting Toward Molecular Classifications· 2024 · 5 citations
2. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial· 2019 · 335 citations
3. Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer· 2022 · 74 citations
4. Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2–, <i>PIK3CA</i>-Mutated Breast Cancer· 2021 · 37 citations
5. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency· 2015 · 9,386 citations